Insight Molecular Diagnostics Inc. Common Stock IMDX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $11.58M+34.1% | $8.64M-8.4% | $9.43M-59.4% | $23.2M-37.8% | ||
| $1.13M-30.1% | $1.61M+233% | $484K-75.9% | $2.01M+40.0% | ||
| $2.07M+222% | $642K— | —— | —— | ||
| $15.31M+30.2% | $11.76M+9.9% | $10.7M-58.1% | $25.54M-34.8% | ||
| $25.76M-26.6% | $35.08M-53.2% | $74.89M-25.2% | $100.09M-37.3% | ||
| $2.54M+55.0% | $1.64M+72.2% | $953K-23.9% | $1.25M-30.8% | ||
| $12.08M+66.0% | $7.28M+1.1% | $7.19M-40.6% | $12.11M-14.3% | ||
| $57.22M+20.8% | $47.36M+18.7% | $39.9M-12.6% | $45.66M-40.5% | ||
| $369.21M+9.2% | $338.24M+9.0% | $310.3M+34.9% | $230M0.0% | ||
| -$400.76M-14.3% | -$350.54M-20.9% | -$289.88M-11.2% | -$260.68M-38.8% | ||
| -$31.46M-156% | -$12.27M-160% | $20.47M-40.3% | $34.29M-47.4% | ||
| $25.76M-26.6% | $35.08M-53.2% | $74.89M-25.2% | $100.09M-37.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Insight Molecular Diagnostics Inc. Common Stock's total assets?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) holds $40.4M in total assets, down 33.0% year over year.
- How much debt does Insight Molecular Diagnostics Inc. Common Stock have?
- Insight Molecular Diagnostics Inc. Common Stock carries $2.9M in total debt against -$10.7M of shareholders' equity, a debt-to-equity ratio of 2.91.
- How much cash does Insight Molecular Diagnostics Inc. Common Stock have?
- Insight Molecular Diagnostics Inc. Common Stock holds $28.2M in cash and equivalents.
- Can Insight Molecular Diagnostics Inc. Common Stock cover its short-term obligations?
- Its current ratio is 2.54 — current assets exceed current liabilities.
- Where does Insight Molecular Diagnostics Inc. Common Stock's balance sheet data come from?
- Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
